Haseltine Lake Kempner Discovered World’s First CASGEVY™ for the Treatment of Sickle Cell Disease
HLK's discovered CASGEVY™ as the world's first approved CRISPR/Cas9 gene-editing therapy for treating both sickle cell disease (SCD) and transfusion-dependant beta thalassaemia (TDT).
"Genetic scissors," often used for CRISPR/Cas9, signifies its ability to precisely cut genetic material, enabling genome editing. Among emerging gene-editing methods, CRISPR/Cas9 stands out for its exceptional precision.
This unique precision has stirred significant excitement and anticipation within the scientific community, marking CRISPR/Cas9 as a transformative advancement in genetic editing.
Following the discovery of CRISPR/Cas9, research teams have extensively used this gene-editing tool to explore its efficacy and applications. They've identified crucial regions within the BCL11A enhancer that regulate foetal haemoglobin (HbF) and identified specific single guide RNA (sgRNA) sequences that increase HbF levels. Boosting HbF production is crucial in treating severe monogenic diseases like sickle cell disease and beta-thalassaemia, which have life-threatening manifestations.
This groundbreaking work offers promising avenues for targeted treatments using CRISPR/Cas9 technology in combating these debilitating conditions.
This therapy's approval marks a major milestone. The clinical trial outcomes showed positive results for almost all patients involved. In the two global clinical trials of CASGEVY™, 28 out of 29 sickle cell patients found relief from severe pain, while 39 out of 42 beta thalassaemia patients did not require blood transfusions for at least a year. These outcomes signal a promising advancement in treating these conditions.
The approval of CASGEVY™ represents a pivotal step towards a future where CRISPR gene-editing can address unmet patient needs. The groundwork established by CASGEVY sets an encouraging precedent for the development and approval of further CRISPR-based therapies.
